Physician profile
Marci W Silverman
NPI 1952307282
$2,943.21
in general payments reported to CMS, 2019-2025
41 companies · $358 in 2025
The $358 reported for 2025 was more than what 80% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $160 · 2021: $413 · 2022: $339 · 2023: $714 · 2024: $673 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $483.49 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $293.72 | 2022-2025 | Azstarys |
| Genzyme Corporation | $217.20 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $193.49 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $176.51 | 2020-2024 | Dyanavel Xr |
| Neurelis, INC. | $114.27 | 2023-2024 | Valtoco |
| Abbvie INC. | $107.46 | 2024-2025 | |
| Adlon Therapeutics L.P. | $106.90 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $83.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.56 | 2019-2024 | Eohilia |
| Alexion Pharmaceuticals, INC. | $79.93 | 2022-2025 | Strensiq, Ultomiris, Koselugo |
| Baxter Healthcare | $67.29 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $66.77 | 2019 | |
| Biomarin Pharmaceutical INC. | $62.42 | 2023 | Brineura, Voxzogo 1.2mg |
| Medtronic, INC. | $59.26 | 2024 | Minimed 780g |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $55.37 | 2023-2025 | Daybue |
| Glaxosmithkline, LLC. | $53.52 | 2021-2023 | Nucala |
| Neos Therapeutics, Lp | $52.99 | 2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Amneal Pharmaceuticals LLC | $50.57 | 2024-2025 | Unithroid |
| Ucb, INC. | $45.86 | 2022-2025 | Fintepla, Briviact |
| Novo Nordisk INC | $45.59 | 2024 | Sogroya, Rivfloza |
| Xeris Pharmaceuticals, INC. | $44.28 | 2021 | |
| Azurity Pharmaceuticals, INC. | $42.70 | 2024-2025 | Zonisade, Triptodur |
| Grifols USA, LLC | $29.98 | 2025 | Xembify |
| Endo USA, INC. | $27.96 | 2025 | Supprelin |
| Qol Medical, LLC | $26.12 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $25.48 | 2025 | Dupixent |
| Ascendis Pharma Endocrinology INC | $25.32 | 2025 | Skytrofa |
| Global Blood Therapeutics, INC. | $24.71 | 2020-2021 | |
| Mirum Pharmaceuticals, INC. | $23.34 | 2023 | Livmarli |
| Catalyst Pharmaceuticals, INC. | $22.44 | 2024 | |
| Covis Pharma Gmbh | $18.87 | 2020 | |
| Collegium Pharmaceutical, INC. | $17.81 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $16.77 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.73 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.37 | 2022 | |
| Tandem Diabetes Care, INC. | $14.89 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $14.51 | 2021 | |
| Greenwich Biosciences, INC. | $13.96 | 2021 | |
| Janssen Biotech, INC. | $13.65 | 2025 | Tremfya |
| Cognoa, INC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marci Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.